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Purpose: To determine the immunophenotypes of macular corneal dystrophy (MCD) in Indian patients and to correlate
them with mutations in the carbohydrate 6-sulfotransferase (CHST6) gene.
Methods: Sixty-four patients from 53 families with MCD that were previously screened for mutations in CHST6 were
included in an immunophenotype analysis. Antigenic keratan sulfate (AgKS) in serum as well as corneal tissue was
evaluated in 31 families. Only cornea was evaluated in 11 families, and only serum was evaluated in 11 families. AgKS
was detected in formalin-fixed, paraffin-embedded corneal sections by immunohistochemistry and in serum by ELISA
using a monoclonal antibody against sulfated forms of KS in patients with MCD as well as normal controls.
Results: Analysis of corneal and/or serum AgKS disclosed MCD type I (27 families), MCD type IA (5 families), and
MCD type II (3 families) in the cases studied. An additional 10 families were either MCD type I or MCD type IA since
only serum AgKS data were available. Seven families manifested atypical immunophenotypes since the corneal AgKS
expression was either of MCD type I or MCD type IA, but serum AgKS levels ranged from 19 ng/ml to 388 ng/ml. More
than one immunophenotype was detected amongst siblings in two families. Each immunophenotype was associated with
mutational heterogeneity in CHST6.
Conclusions: MCD type I was the predominant immunophenotype in the Indian population studied followed by MCD
type IA and then MCD type II. We detected further immunophenotypic heterogeneity by finding atypical patterns of AgKS
reactivity in a subset of families. There were no simple correlations between immunophenotypes and specific mutations in
CHST6, suggesting that factors other than CHST6 mutations may be contributing to the immunophenotypes in MCD.
Macular corneal dystrophy (MCD; OMIM 217800) is an
autosomal  recessive  disorder  characterized  clinically  by
bilateral  diffuse  clouding  of  the  corneal  stroma  and  the
presence of grayish-white, punctate opacities especially in the
superficial  cornea.  Histologically,  the  cornea  in  MCD  is
characterized by the accumulation of extracellular deposits in
the stroma and Descemet membrane as well as by intracellular
storage of similar material in the keratocytes and corneal
endothelium. The deposits stain with Alcian blue and other
histochemical methods for glycosaminoglycans (GAGs) [1].
Biochemical studies based on organ cultures of corneas as
well as analyses of serum in patients with MCD suggested that
the basic defect in MCD lies in a sulfotransferase specific for
sulfation  of  keratan  sulfate  (KS)  proteoglycan  [2-7].
Molecular genetic studies on MCD led to the mapping of the
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MCD gene [8] and subsequently to the identification of the
carbohydrate 6-sulfotransferase (CHST6) gene, which codes
for corneal N-acetyl glucosamine 6-sulfotransferase, as the
cause for MCD [9].
Although  MCD  is  clinically  homogeneous,  three
immunophenotypes  have  been  recognized  based  on  the
reactivity of the cornea and serum in patients with MCD to a
monoclonal  antibody,  5D4,  which  is  specific  for  highly
sulfated epitopes on KS [10-13]. MCD type I is characterized
by the absence or very low levels of antigenic keratan sulfate
(AgKS) in the cornea and serum. MCD type II is characterized
by the presence of normal or slightly reduced levels of AgKS
in serum and an immunohistochemical reactivity for AgKS in
the corneal stroma, keratocytes, Descemet membrane, and
endothelial cells [10]. In addition, a third immunophenotype
(MCD type IA) is characterized by an absence or very low
level  of  serum  AgKS  accompanied  by  detectable  AgKS
reactivity in keratocytes [11]. The deposits in MCD type I
were further shown to be unsulfated by Erythrina crystagalli
agglutinin  labeling,  which  recognizes  unsulfated  keratan
sulfate proteoglycan (KSPG) [13]. Akama and coworkers [9]
suggested that MCD types I and II were distinguishable by the
nature of CHST6 mutations. They observed that MCD type II
was  associated  with  a  deletion  or  rearrangement  of  the
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319upstream region of CHST6 and proposed that MCD type II is
characterized by an absence of coding region mutations in one
or both alleles [9]. However, deviations from this pattern have
been observed in subsequent studies [14,15]. Despite the fact
that  the  immunophenotypes  of  MCD  do  not  seem  to  be
clinically relevant, we wanted to determine the prevalence of
different MCD subtypes in Indian patients and to evaluate the
relation  of  CHST6  mutations  with  the  aforementioned
immunophenotypes in a series of 53 Indian families with
MCD in whom mutational data on CHST6 was available [16,
17].
METHODS
The study had the approval of the Institutional Review Board
of  the  L.  V.  Prasad  Eye  Institute  (Hyderabad,  India)  and
conformed  to  the  tenets  of  the  Declaration  of  Helsinki.
Informed consent was obtained from all participants, and 4 ml
of peripheral blood was collected from each participant for
serum analysis of AgKS. The diagnosis of MCD was based
on the distinct clinical features (as described previously [16]),
and in 48 patients this was confirmed by a histopathologic
examination  of  the  excised  corneal  buttons  obtained  at
penetrating keratoplasty. All patients included in the present
study were from the cohort previously screened for mutations
in CHST6 [16,17].
Immunohistochemistry  was  performed  on  4  μ  thick
sections of paraffin-embedded formalin-fixed corneas from
48  MCD  patients  from  42  families  (55  total  corneas).
Monoclonal primary antibody directed specifically against
sulfated epitopes present on KS (1/20/5-D-4 mouse IgG; ICN
Pharmaceuticals Inc., Irvine, CA) was used for detection of
AgKS  in  the  cornea.  The  secondary  antibody  used  was
biotinylated  anti-mouse  IgG  (DakoCytomation,  Glostrup,
Denmark). Detection was done by the avidin-biotin complex
immunoperoxidase  technique  in  which  avidin-conjugated
peroxidase binds to the biotinylated antibody followed by
detection  of  peroxidase  after  the  addition  of  a  suitable
substrate,  3,3′-diaminobenzidine  tetrahydrochloride  (DAB;
Sigma-Aldrich, St. Louis, MO) [18]. The primary antibody
was used at a dilution of 1:700, which was determined as the
optimum dilution by testing different antibody dilutions using
corneas from positive (normal) controls that included patients
with congenital hereditary endothelial dystrophy 2 (CHED2)
or granular corneal dystrophy (GCD) in which KS is expected
to be normal. As a negative control, the primary antibody was
omitted  and  phosphate-buffered  saline  was  used.
Interpretations of immunohistochemical assays were made
independently  by  four  investigators,  each  masked  to  the
findings of the others.
Estimation of serum AgKS: Serum AgKS levels were
determined in 51 MCD patients from 42 families and five
unaffected relatives from 5 families by the enzyme-linked
immunosorbent assay (ELISA) using the 1/20/5-D4 anti-KS
monoclonal antibody as described previously [19]. Serum
AgKS levels that were less than or equal to 8 ng/ml were
interpreted as MCD types I/IA and levels of 100 ng/ml or
above as normal or MCD type II.
RESULTS
Immunophenotypes:  Fifty-three  families  with  MCD  (64
patients)  were  evaluated  for  the  AgKS  reactivity  of  their
corneal tissue and/or serum. Representative corneas showing
the three different immunophenotypes are illustrated in Figure
1A-C. Levels of AgKS were assessed in both the cornea and
serum of 31 families (35 patients) and in either cornea or
serum in 22 families.
Of these, AgKS levels corresponding to MCD type I were
found in 31 patients from 27 families (patients 1–31; Table 1)
based on analyses of both the cornea and serum in at least one
affected individual (20 families) and of only the cornea (7
families). More than one individual was available for this
study in two families, and different members within each
family showed similar patterns of AgKS (patients 21–22 and
28–31; Table 1).
Five families (7 patients [# 32–38]; Table 1) had a pattern
corresponding  with  MCD  type  IA  as  assessed  by  AgKS
reactivity in the cornea or in both cornea and serum (Table 1).
Two families each had two affected members (patients 32, 33
and  patients  37,38)  who  showed  the  same
immunophenotypes.
MCD type II was found in two unrelated patients (patients
39, 40) as indicated by corneal AgKS reactivity.
Eleven  families  (13  patients)  were  grouped  into
immunophenotypes based only on serum levels on AgKS
since  corneal  tissues  were  unavailable.  The  serum  AgKS
levels in 10 families (11 patients) were less than 8 ng/ml,
corresponding to MCD types I or IA (patients 43–53; Table
1)  whereas  in  one  family  with  two  affected  individuals
(patients 41 and 42; Table 1), serum AgKS corresponded to
MCD type II (105 ng/ml; patient 41) or possibly to an atypical
pattern (patient 42; 42 ng/ml).
Apart  from  the  three  immunophenotypes  mentioned
above, there were seven families (7 patients) who showed
AgKS reactivity that did not conform to any of the three types
described and were therefore considered as atypical (patients
54–60;  Table  1).  These  included  four  patients  from  four
families with no detectable AgKS in the cornea (MCD type I
pattern) and serum AgKS levels ranging from 19ng/ml to 63
ng/ml. The remaining three patients had detectable AgKS only
in keratocytes (similar to MCD type IA) with serum AgKS
levels ranging from 95 ng/ml to 388 ng/ml. Serum levels of
AgKS in the three patients mentioned above are in the range
of values for MCD type II.
Different immunophenotypes associated with the same
CHST6  mutation  within  a  family  were  observed  in  two
families (Table 1). Two members (patients 60, 61) from one
family showed either an ‘atypical’ immunophenotype (patient
Molecular Vision 2009; 15:319-325 <http://www.molvis.org/molvis/v15/a32> © 2009 Molecular Vision
32060, mentioned above) or a corneal immunoreactivity of MCD
Figure 1. Immunophenotypes of MCD. Light microscopic images of
representative corneas show different immunophenotypes of MCD
(stained  with  diaminobenzidine  [DAB],  counterstained  with
hematoxylin-eosin). A: A cornea with the absence of detectable
AgKS is shown (MCD type I; DAB; 40X). B: A cornea is shown
with reactivity to AgKS only in stromal keratocytes (MCD type IA;
DAB; 100X). C: A cornea is shown with AgKS detected throughout
the stroma (MCD type II; DAB; 100X). Arrowheads point to the
deposits in stromal keratocytes.
type IA (patient 61). In the second family, three members
(patients 62–64; Table 1) were evaluated for both serum and
corneal AgKS. The proband (patient 62) had the MCD type II
phenotype whereas the two other members, the spouse and
child (patients 63, 64), had MCD types IA and I, respectively
(Table  1).  Photomicrographs  of  corneal  sections  of  two
members of this family are shown in Figure 2A,B.
DISCUSSION
This study examined immunophenotypes in MCD in relation
to the mutational status of CHST6 in MCD patients of Indian
origin. The existence of distinct immunophenotypes of MCD
has been well documented [10-12,20], and yet their biological
or clinical significance remains unclear. Though a mutation in
CHST6, presumed to lead to the absence of sulfation of KS
precursors, is established as the cause of MCD, the presence
of  sulfated  epitopes  that  are  recognizable  by  the  5D4
monoclonal antibody in the cornea and/or serum of a subset
of MCD patients suggests a further level of complexity in the
pathogenesis of MCD. Understanding the molecular basis of
the  MCD  immunophenotypes  may  lead  to  a  better
comprehension of the pathobiology of this inherited corneal
disease.
The present study revealed that MCD type I is the most
frequent immunophenotype in Indian patients. Taking into
account those patients with their corneal and serum levels of
AgKS evaluated, MCD type I, which was seen in 63% of
patients  (22/35  patients  or  20/31  families),  was  the  most
common followed by MCD type IA, which was seen in 14%
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Correlations between mutations and immunophenotypes:
MCD type I—Of the 27 families with MCD type I (Table
1), 10 different missense mutations were found in 11 families,
three nonsense mutations in three families, five frameshift
mutations  in  seven  families,  and  two  in-frame  insertion
mutations  in  six  families.  Homozygous  mutations  were
identified in all families.
Similar  mutational  heterogeneity  was  observed  in
families grouped as either MCD type I or MCD IA based on
serum Ag KS levels (Table 1).
MCD type IA—Of the five families classified as MCD
type  IA  based  on  corneal  AgKS,  four  families  had  three
missense mutations with one mutation, Asp221Glu, in two
families, and the fifth family had an in-frame insertion (Table
1).
MCD type II—MCD type II was found in association
with  a  single  heterozygous  frameshift  mutation
(Phe67SerfsX3) in one family (patient 39), two homozygous
mutations, Trp2Ter and Leu3Met, in one family (patient 40),
and with no detectable mutations in another family (patient
41; Table 1).
Atypical immunophenotypes—Patients with ‘atypical’
immunophenotypes (Table 1) showed missense mutations (6
families), nonsense mutations (1 family), and no detectable
mutation (1 family). Of these, one family (patient 56) had a
single heterozygous mutation (Ser98Leu; Table 1).TABLE 1. IMMUNOPHENOTYPES AND ASSOCIATED MUTATIONS IN PATIENTS WITH MCD.
Patient
number
Reactivity to KS antibody in
 Serum
  AgKS
 (ng/ml)
Type of
mutation Mutation
MCD
 type Stroma               Keratocytes
1 -ve -ve <4 Frameshift p.Ser32GlnfsX36 I
2 -ve -ve <2 Missense p.Gly52Asp I
3 -ve -ve Not done Missense Ser53Leu I
4 -ve -ve <4 Missense p.Phe107Ser I
5 -ve -ve <4 Missense p.Phe107Ser I
6 -ve -ve Not done Nonsense p.Trp123X I
7 -ve -ve <4 Nonsense p.Cys153X I
8# -ve -ve <2 Insertion p.Arg195–196ins I
9 -ve -ve <4 Missense p.Pro204Gln I
10# -ve -ve <2 Frameshift p.Arg205TrpfsX176 I
11 -ve -ve 6 Insertion p.Trp219–220ins I
12 -ve -ve <4 Insertion p.Trp219–220ins I
13 -ve -ve <4 Insertion p.Trp219–220ins I
14 -ve -ve <4 Nonsense p.Glu347X I
15 -ve -ve 5 Frameshift p.Val6ProfsX55 I
16 -ve -ve 6 Missense p.Ser54Phe I
17 -ve -ve 7 Frameshift p.Phe60LeufsX10 I
18 -ve -ve 8 Frameshift p.Phe60LeufsX10 I
19 -ve -ve Not done Missense Cys165Ser I
20 -ve -ve Not done Missense Cys165Trp I
21A -ve -ve <2 Missense p.Pro204Arg I
22A Not done Not done <2 Missense p.Pro204Arg I
23 -ve -ve <2 Insertion p.Trp219–220ins I
24 -ve -ve Not done Insertion p.Trp219–220ins I
25 -ve -ve <2 Missense p.Asp221Tyr I
26 -ve -ve Not done Missense p.Arg334Cys I
27 -ve -ve Not done Frameshift p.His335CysfsX27 I
28B -ve -ve <4 Frameshift p.His335CysfsX27 I
29B -ve -ve <2 Frameshift p.His335CysfsX27 I
30B Not done Not done <2 Frameshift p.His335CysfsX27 I
31B Not done Not done <2 Frameshift p.His335CysfsX27 I
32C -ve +ve <4 Missense p.[Ser98Trp]+[Phe107Ser] IA
33C -ve +ve <4 Missense p.[Ser98Trp]+[Phe107Ser] IA
34 -ve +ve <4 Missense p.Phe121Ser IA
35 -ve +ve <4 Insertion p.Trp219–220ins IA
36 -ve +ve Not done Missense p.Asp221Glu IA
37#D -ve +ve Not done Missense p.Asp221Glu IA
38#D -ve +ve Not done Missense p.Asp221Glu IA
39 +ve +ve not done Frameshift p.[Phe67SerfsX3]+[=] II
40 +ve +ve not done Nonsense
+missense
p.[Trp2X;Leu3Met]+ [Trp2X;Leu3Met] II
41E Not done Not done 105 - No CHST6 mutation II?
42E Not done Not done 42 - No CHST6 mutation II/atypical?
43 Not done Not done <4 Missense p.Gly52Asp I/IA
44 Not done Not done <4 Frameshift p.Phe60LeufsX10 I/IA
45 Not done Not done <4 Nonsense p.Gly309X I/IA
46 Not done Not done <4 Missense p.[Val56Arg]+ [Ser167Phe] I/IA
47 Not done Not done <4 Missense p.Ala73Thr I/IA
48 Not done Not done 8 Nonsense p.Trp123X I/IA
49 Not done Not done <4 Missense p.Ser131Pro I/IA
50F Not done Not done <4 Frameshift+
Missense
[Gln182ArgfsX199]+ [Leu276Pro] I/IA
51F Not done Not done <4 Missense p.Leu276Pro I/IA
52 Not done Not done <2 Missense p.Leu193Pro I/IA
53 Not done Not done <2 Missense p.Arg272Ser I/IA
54 -ve -ve 63 Nonsense p.Gln18X Atypical
55 -ve +ve 95 Missense p.Asp221Glu Atypical
56 -ve +ve 388 Missense p.[Ser98Leu]+[=] Atypical
57 -ve -ve 33 Missense p.Phe178Cys Atypical
58 -ve -ve 19 Missense p.Arg202Ser Atypical
59 -ve +ve 142 Missense p.Asp221Glu Atypical
60G -ve -ve 61 Missense p.[Ser210Phe]+[Asp221Glu] Atypical
61G -ve +ve Not done Missense p.[Ser210Phe]+[Asp221Glu] IA?
62H +ve +ve 101 Missense Asp221Tyr II
63H -ve +ve <4 Missense Asp221Tyr IA
64H -ve -ve 6 Missense Asp221Tyr I
Details of serum and corneal AgKS reactivity, associated CHST6   mutations and corresponding MCD immunophenotypes are
listed for all patients studied. Reactivity to AgKS in cornea is denoted as present (+ve) or absent (-ve). Mutations in the protein
are as described earlier [16,17]. Members of the same family are denoted by letters A-H in superscripts. The sharp (hash mark
‘#’) indicates patients that had both corneas evaluated.
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II, which was seen in 3% of patients (1/35 patients or 1/31
families). The predominance of MCD type I over other types
is similar to that found in studies on MCD patients from
various  regions  including  Iceland,  Saudi  Arabia,  southern
India,  and  the  United  States  [11,12,15,21,22].  A  similar
frequency of MCD types I and IA was reported in a study on
German patients [23].
An unusual feature observed in the present study was that
seven  families  showed  ‘atypical’  immunophenotypes  in
which the values of serum AgKS ranged from 19 ng/ml to 388
ng/ml,  although  immunohistochemical  analysis  of  these
corneal sections showed little or no reactivity to AgKS, which
would depict immunophenotypes MCD type I or MCD type
IA. While the reasons for this are not currently understood, it
may  indicate  further  immunophenotypic  heterogeneity  in
MCD. Complex immunophenotypes were also observed in a
previous study by Iida-Hasegawa and coworkers [24] who
found that a patient with serum AgKS corresponding to MCD
type I had positive reactivity to AgKS in the stroma and
extracellular accumulations. Moreover, patients with serum
AgKS levels compatible with MCD type II in their study
showed  no  stromal  reactivity  to  AgKS  on
immunohistochemistry [24].
We  found  no  clear-cut  correlations  between
immunophenotypes  and  mutations  in  CHST6.  Mutational
heterogeneity was seen within each subtype of MCD. The
same mutation was found to be associated with more than one
immunophenotype. Of these, one mutation, Asp221Tyr, was
found  in  patients  from  a  single  family  with  all  three
immunophenotypes  while  two  other  mutations,  Trp219–
220ins and Phe107Ser, were associated with MCD types I and
IA. There were two recurrent mutations in our series, each
found in six families, an insertion mutation, Trp219–220ins,
and a missense mutation, Asp221Glu. Each was associated
predominantly  with  one  immunophenotype  among  the
patients studied. Trp219–220ins was present in five families
with MCD type I and in one family with MCD type IA (Table
1). The Asp221Glu mutation was predominantly found in
association  with  a  corneal  phenotype  of  MCD  type  IA
(patients 36–38, 55, 59, 61; Table 1) as well as with MCD type
I in one patient (patient 60). However, serum AgKS values in
three of these families showed atypical patterns (patients 55,
59, 60).
It  is  noteworthy  that  all  three  MCD  subtypes  were
observed  in  one  family,  which  was  associated  with  the
mutation,  Asp221Tyr.  The  concordance  between  serum
AgKS and corneal AgKS reactivity in each member of this
family makes it unlikely that the variable immunoreactivity
within the family is due to artifacts of detection. The presence
of both MCD types I and II has also been noted previously in
an Icelandic family, although with different but overlapping
combinations of CHST6 alleles [25,26].
There were very few patients with MCD type II in our
series. A recurrent feature observed in different studies to date
is that patients with MCD type II have no detectable mutations
in the coding region and/or upstream region on one or both
alleles  of  CHST6  [14,15,21,22],  although  contradictory
observations have been reported in some cases [14,26]. The
predicted effect of mutations in the upstream (regulatory)
regions and the absence of coding region mutations is that
CHST6 alleles in MCD type II would retain more enzymatic
activity as compared to those responsible for MCD type I. We
noted  the  occurrence  of  a  single  heterozygous  mutation
(patient 39; Table 1) or no detectable mutations in CHST6
(patient 41; Table1) in two out of three families with MCD
type II. It is worth noting that the other occurrence of a single
Figure  2.  Different  corneal  immunophenotypes  among  affected
members of a family with MCD. A: Corneal section from patient 62
having MCD type II, showing staining for AgKS throughout the
stroma and in keratocytes. B: Corneal section from patient 63 from
the same family, having MCD type IA. Staining for AgKS is seen
only in corneal keratocytes, and is completely absent in the stroma
(details  in  Table  1;  stained  with  DAB,  counterstained  with
hematoxylin-eosin and periodic acid Schiff, 400X).
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corneal phenotype of MCD type IA but with normal levels of
serum AgKS (patient 56; Table 1). Previous analysis in these
patients with an absence of mutations in the coding region
failed to detect mutations in the upstream region of CHST6
[16,17]. Apart from these, one family with MCD type II in our
study (patient 40; Table 1) had a double homozygous change
of Trp2X and Leu3Met. An interesting possibility that needs
to be explored further is that though a nonsense mutation
Trp2X occurs at the second codon, a Leu3Met mutation in the
next codon may generate a protein that is at least partially
active due to re-initiation at codon 3 of the wild type protein.
In  the  background  of  the  available  literature  and  the
results of the present study, the molecular basis of different
immunophenotypes of MCD may not be readily explainable
only on the basis of mutations in CHST6. KS is one of the
major GAGs of the corneal stroma and plays an important role
in corneal transparency. The variable presence of sulfated KS
in cornea or serum of patients with CHST6 mutations may be
explained by a possible redundancy in KS sulfation activity
both within the cornea and other tissues. Corneal N-acetyl
glucosamine 6-sulfotransferase has been shown to efficiently
catalyze  the  sulfation  of  endothelial  mucin,  which  is  the
substrate for intestinal N-acetyl glucosamine sulfotransferase,
thus showing that there is an overlap in activity with the
intestinal sulfotransferase [27]. These possibilities, however,
do not explain the absence of any clinical differences between
MCD  patients  with  different  immunophenotypes.  A
biochemical evaluation of the enzymatic activities of proteins
encoded by CHST6 mutations associated with MCD type II
versus mutations associated with MCD type I may reveal
whether there are differences in activity between the two
groups of mutants.
Data from the present study, which involved analysis of
a large series of MCD patients from the same geographic
origin, show complexity of immunophenotypes in MCD and
suggest  further  immunophenotypic  heterogeneity  than
previously described. The different immunophenotypes might
be determined by factors other than or in addition to CHST6
mutations.
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